News – Page 1073 – Endpoints News

Sanuj Ravindran to lead PellePharm as CEO; Paul Hastings leaves OncoMed; Moderna taps John Mendlein as president

8 years ago

Lundbeck partners with Vanderbilt on new schizophrenia drug; Peregrine officially renamed Avid BioServices in pursuit ...

8 years ago

Kala Pharma shares damaged by mixed data from PhIII dry eye program

8 years ago

China's KBP Bio is coming to America, with $76M A round and GSK vet taking the helm in Philly

8 years ago

Neurodegeneration star Denali nabs a cash-rich, $1B-plus Alzheimer’s partnership with Takeda

8 years ago

Takeda swoops in to buy stem cell partner TiGenix for $630M, putting it on the threshold of a likely approval

8 years ago

Faheem Hasnain and his ex-Receptos team launch a new biotech with $100M and a twist on the old biotech model

8 years ago

SVB's crystal ball points to big money biotech IPOs, downshift in the torrid pace of venture investing

8 years ago

INC Research and inVentiv Health come under Syneos Health brand in closing chapter of CRO merger

8 years ago

Biotech investapalooza continues with more venture rounds for startups; OvaScience cuts half of its workforce (again)

8 years ago

On a roll, MacroGenics allies with Roche on a bispecific development campaign

8 years ago

Atlas builds its dream team and hands over $25M to launch a new approach to gene therapy

8 years ago

What break? Sarepta vet Ed Kaye quickly pivots to the helm of another biotech upstart with a $40M bankroll

8 years ago

Novartis backs eye drop maker in $20M round, meds to fill gap left by Eylea/Lucentis

8 years ago

BioNTech raises mammoth $270M A round, nearing $1B mark as investors continue a love affair with mRNA

8 years ago

Pfizer lines up an $830M alliance with Arvinas on protein degradation

8 years ago

Allergan axing 1,000-plus jobs, prepping for a painful onslaught of Restasis knockoffs

8 years ago

Celgene and bluebird make a 'breakthrough' on BCMA-targeting CAR-T; Another cancer drug biotech garners $39M startup ...

8 years ago

All in: Boehringer Ingelheim more than doubles its venture fund to €250M

8 years ago

Pfizer doubles down on Sangamo’s zinc finger tech, adding ALS to a mix of gene therapy alliances

8 years ago

The gene therapy pricing debate gets real as Spark sets $850,000 charge for its pioneering drug

8 years ago

Upstart Expansion bags a $55M launch round to join the hunt for RNA-targeting small molecules

8 years ago

John Mendlein steps in to help focus on the big picture at a fast-growing Moderna

8 years ago

Biogen vet Jean-Paul Kress takes the reins at NYC's Syntimmune

8 years ago

First page Previous page 1070 1071 107210731074 1075 1076 Next page Last page